search button

Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

  • Authors:
    • Seyda Gündüz
    • Sema Sezgin Göksu
    • Deniz Arslan
    • Ali Murat Tatli
    • Mükremin Uysal
    • Umut Rıza Gündüz
    • Mert Mahsuni Sevinç
    • Hasan Senol Coşkun
    • Hakan Bozcuk
    • Hasan Mutlu
    • Burhan Savas

  • View Affiliations

  • Published online on: July 21, 2015     https://doi.org/10.3892/mco.2015.610
  • Pages: 1109-1112
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is the most frequently diagnosed cancer in women worldwide and the second cause of cancer‑related mortality. A total of 20‑30% of patients with early‑stage breast cancer develop recurrence within the first 5 years following diagnosis. Trastuzumab significantly improves overall survival and disease‑free survival (DFS) in women with human epidermal growth factor receptor 2 (HER2)‑positive early and locally advanced breast cancer. This study aimed to determine the factors that affect DFS following adjuvant transtuzumab therapy. A total of 62 patients treated with trastuzumab for early and locally advanced breast cancer were included in our study. data, including pathology, treatment and treatment outcome, rate of recurrence and laboratory tests, were retrospectively collected. There was no significant association between DFS and age, menopausal status, disease stage and hormone receptor status. The median follow‑up was 48.4 months. The median DFS of patients treated with adjuvant trastuzumab was 64.1 months. In addition, the median DFS was 44.3 vs. 66.8 months in patients with platelet‑lymphocyte ratio (PLR) ≤200 vs. >200, respectively (log‑rank test; P=0.001), and 70 vs. 45 months in patients with eosinophil count ≤70 vs. >70x103̸mm3 (log‑rank test; P=0.001). Our data revealed the prognostic relevance of a decrease in the peripheral blood eosinophil count and PLR value following trastuzumab therapy in breast cancer. PLR and eosinophil count measurements are cost‑effective, readily available worldwide, non‑invasive and safe. Combined with other markers, such as patient age, tumor stage and tumor histology, may be effectively used for patients with breast cancer.
View Figures
View References

Related Articles

Journal Cover

September-2015
Volume 3 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Mutlu H, et al: Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol Clin Oncol 3: 1109-1112, 2015
APA
Gündüz, S., Göksu, S.S., Arslan, D., Tatli, A.M., Uysal, M., Gündüz, U.R. ... Savas, B. (2015). Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Molecular and Clinical Oncology, 3, 1109-1112. https://doi.org/10.3892/mco.2015.610
MLA
Gündüz, S., Göksu, S. S., Arslan, D., Tatli, A. M., Uysal, M., Gündüz, U. R., Sevinç, M. M., Coşkun, H. S., Bozcuk, H., Mutlu, H., Savas, B."Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab". Molecular and Clinical Oncology 3.5 (2015): 1109-1112.
Chicago
Gündüz, S., Göksu, S. S., Arslan, D., Tatli, A. M., Uysal, M., Gündüz, U. R., Sevinç, M. M., Coşkun, H. S., Bozcuk, H., Mutlu, H., Savas, B."Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab". Molecular and Clinical Oncology 3, no. 5 (2015): 1109-1112. https://doi.org/10.3892/mco.2015.610